Huluwa announced that it has recently received the “Drug Registration Certificate” for the atomized inhalation solution of levosalbutamol hydrochloride approved and issued by the State Drug Administration. This medicine is an inhaled preparation and is suitable for treating or preventing bronchospasm in adults and children over 6 years of age. The original formulation was not marketed domestically. After approval, it was treated as if it had passed the generic drug consistency evaluation. In addition to the company, 22 domestic companies also received approval numbers. The company has invested a total of 5.7097 million yuan in R&D expenses for this product. However, there is uncertainty about drug sales performance.

Huluwa announced that it has recently received the “Drug Registration Certificate” for the atomized inhalation solution of levosalbutamol hydrochloride approved and issued by the State Drug Administration. This medicine is an inhaled preparation and is suitable for treating or preventing bronchospasm in adults and children over 6 years of age. The original formulation was not marketed domestically. After approval, it was treated as if it had passed the generic drug consistency evaluation. In addition to the company, 22 domestic companies also received approval numbers. The company has invested a total of 5.7097 million yuan in R&D expenses for this product. However, there is uncertainty about drug sales performance.